Signs Of Inflammation Research Articles

Altered X-chromosome inactivation predisposes to autoimmunity.

In mammals, males and females show marked differences in immune responses. Males are globally more sensitive to infectious diseases, while females are more susceptible to systemic autoimmunity. X-chromosome inactivation (XCI), the epigenetic mechanism ensuring the silencing of one X in females, may participate in these sex biases. We perturbed the expression of the trigger of XCI, the noncoding RNA Xist, in female mice. This resulted in reactivation of genes on the inactive X, including members of the Toll-like receptor 7 (TLR7) signaling pathway, in monocyte/macrophages and dendritic and B cells. Consequently, female mice spontaneously developed inflammatory signs typical of lupus, including anti-nucleic acid autoantibodies, increased frequencies of age-associated and germinal center B cells, and expansion of monocyte/macrophages and dendritic cells. Mechanistically, TLR7 signaling is dysregulated in macrophages, leading to sustained expression of target genes upon stimulation. These findings provide a direct link between maintenance of XCI and female-biased autoimmune manifestations and highlight altered XCI as a cause of autoimmunity.

Ototoxicity: a high risk to auditory function that needs to be monitored in drug development.

Hearing loss constitutes a major global health concern impacting approximately 1.5 billion people worldwide. Its incidence is undergoing a substantial surge with some projecting that by 2050, a quarter of the global population will experience varying degrees of hearing deficiency. Environmental factors such as aging, exposure to loud noise, and the intake of ototoxic medications are implicated in the onset of acquired hearing loss. Ototoxicity resulting in inner ear damage is a leading cause of acquired hearing loss worldwide. This could be minimized or avoided by early testing of hearing functions in the preclinical phase of drug development. While the assessment of ototoxicity is well defined for drug candidates in the hearing field - required for drugs that are administered by the otic route and expected to reach the middle or inner ear during clinical use - ototoxicity testing is not required for all other therapeutic areas. Unfortunately, this has resulted in more than 200 ototoxic marketed medications. The aim of this publication is to raise awareness of drug-induced ototoxicity and to formulate some recommendations based on available guidelines and own experience. Ototoxicity testing programs should be adapted to the type of therapy, its indication (targeting the ear or part of other medications classes being potentially ototoxic), and the number of assets to test. For multiple molecules and/or multiple doses, screening options are available: in vitro (otic cell assays), ex vivo (cochlear explant), and in vivo (in zebrafish). In assessing the ototoxicity of a candidate drug, it is good practice to compare its ototoxicity to that of a well-known control drug of a similar class. Screening assays provide a streamlined and rapid method to know whether a drug is generally safe for inner ear structures. Mammalian animal models provide a more detailed characterization of drug ototoxicity, with a possibility to localize and quantify the damage using functional, behavioral, and morphological read-outs. Complementary histological measures are routinely conducted notably to quantify hair cells loss with cochleogram. Ototoxicity studies can be performed in rodents (mice, rats), guinea pigs and large species. However, in undertaking, or at the very least attempting, all preclinical investigations within the same species, is crucial. This encompasses starting with pharmacokinetics and pharmacology efficacy studies and extending through to toxicity studies. In life read-outs include Auditory Brainstem Response (ABR) and Distortion Product OtoAcoustic Emissions (DPOAE) measurements that assess the activity and integrity of sensory cells and the auditory nerve, reflecting sensorineural hearing loss. Accurate, reproducible, and high throughput ABR measures are fundamental to the quality and success of these preclinical trials. As in humans, in vivo otoscopic evaluations are routinely carried out to observe the tympanic membrane and auditory canal. This is often done to detect signs of inflammation. The cochlea is a tonotopic structure. Hair cell responsiveness is position and frequency dependent, with hair cells located close to the cochlea apex transducing low frequencies and those at the base transducing high frequencies. The cochleogram aims to quantify hair cells all along the cochlea and consequently determine hair cell loss related to specific frequencies. This measure is then correlated with the ABR & DPOAE results. Ototoxicity assessments evaluate the impact of drug candidates on the auditory and vestibular systems, de-risk hearing loss and balance disorders, define a safe dose, and optimize therapeutic benefits. These types of studies can be initiated during early development of a therapeutic solution, with ABR and otoscopic evaluations. Depending on the mechanism of action of the compound, studies can include DPOAE and cochleogram. Later in the development, a GLP (Good Laboratory Practice) ototoxicity study may be required based on otic related route of administration, target, or known potential otic toxicity.

Exploring the dynamic three-dimensional chromatin architecture and transcriptional landscape in goose liver tissues underlying metabolic adaptations induced by a high-fat diet

BackgroundGoose, descendants of migratory ancestors, have undergone extensive selective breeding, resulting in their remarkable ability to accumulate fat in the liver and exhibit a high tolerance for significant energy intake. As a result, goose offers an excellent model for studying obesity, metabolic disorders, and liver diseases in mammals. Although the impact of the three-dimensional arrangement of chromatin within the cell nucleus on gene expression and transcriptional regulation is widely acknowledged, the precise functions of chromatin architecture reorganization during fat deposition in goose liver tissues still need to be fully comprehended.ResultsIn this study, geese exhibited more pronounced changes in the liver index and triglyceride (TG) content following the consumption of the high-fat diet (HFD) than mice without significant signs of inflammation. Additionally, we performed comprehensive analyses on 10 goose liver tissues (5 HFD, 5 normal), including generating high-resolution maps of chromatin architecture, conducting whole-genome gene expression profiling, and identifying H3K27ac peaks in the livers of geese and mice subjected to the HFD. Our results unveiled a multiscale restructuring of chromatin architecture, encompassing Compartment A/B, topologically associated domains, and interactions between promoters and enhancers. The dynamism of the three-dimensional genome architecture, prompted by the HFD, assumed a pivotal role in the transcriptional regulation of crucial genes. Furthermore, we identified genes that regulate chromatin conformation changes, contributing to the metabolic adaptation process of lipid deposition and hepatic fat changes in geese in response to excessive energy intake. Moreover, we conducted a cross-species analysis comparing geese and mice exposed to the HFD, revealing unique characteristics specific to the goose liver compared to a mouse. These chromatin conformation changes help elucidate the observed characteristics of fat deposition and hepatic fat regulation in geese under conditions of excessive energy intake.ConclusionsWe examined the dynamic modifications in three-dimensional chromatin architecture and gene expression induced by an HFD in goose liver tissues. We conducted a cross-species analysis comparing that of mice. Our results contribute significant insights into the chromatin architecture of goose liver tissues, offering a novel perspective for investigating mammal liver diseases.

Recombinant Human Proteoglycan Aggrecan-G1 Domain-induced Arthritis (GIA) Mouse Model.

The recombinant human proteoglycan aggrecan-G1 domain (rhG1)-induced arthritis (GIA) mouse model is a complex model of rheumatoid arthritis (RA). In GIA, autoimmune arthritis is induced by repeated intraperitoneal immunization of genetically susceptible BALB/c mice with the rhG1 antigen emulsified in the adjuvant dimethyldioctadecylammonium (DDA). This article describes the steps for producing and purifying the rhG1 antigen, the immunization protocol, methods for following the clinical picture of arthritis, and the evaluation of relevant laboratory parameters. In this model, the autoimmune arthritis develops stepwise, similar to RA: First is the preclinical stage (after the first immunization, days 0-20) with no sign of inflammation but detectable T and B cell activation; next, the stage of early arthritis (after the second immunization, days 21-41), where the first definitive signs of arthritis appear together with autoantibody production; and then the severe late-stage arthritis (after the third immunization, after day 42), which presents with massive inflammation of the limbs, leading to cartilage and bone destruction and finally ankylosis. The protocols described here provide sufficient information for investigators to use the GIA model to study different aspects of autoimmune arthritis. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol: Induction of recombinant human proteoglycan aggrecan-G1 domain (rhG1)-induced arthritis (GIA) Support Protocol 1: Production of rhG1-Xa-mFc2a fusion protein with CHOK1 mammalian expression system Support Protocol 2: Purification of the rhG1-Xa-mFc2a fusion protein by affinity chromatography Support Protocol 3: Preparation of DDA adjuvant Support Protocol 4: Clinical assessment of arthritis Support Protocol 5: Measurement of serum antibody levels and cytokines Support Protocol 6: Measurement of rhG1-induced proliferation and cytokine production in spleen cell culture Support Protocol 7: Histological assessment of arthritic limbs Support Protocol 8: Evaluation of arthritis with micro-computed tomography.

Study on the susceptibility of bovine coronavirus to BALB/c mice

There are no other bovine coronavirus (BCoV) infection models except calves, which makes efficacy evaluation of vaccines and pathogenic mechanism research of BCoV inconvenient owing to their high value and inconvenient operation. This study aimed to establish a mouse model of BCoV infection. BCoV was used to infect 4-week-old male BALB/c mice and the optimal infection conditions were screened, including the following infection routes: gavage, intraperitoneal injection, and tail vein injection at doses of 1 × 108 TCID50, 2 × 108 TCID50 and 4 × 108 TCID50. Using the optimal infection conditions, BALB/c mice were infected with BCoV, and their body weight, blood routine, inflammatory factors, autopsy, virus distribution, and viral load were measured at 1, 3, 5, and 7 days after infection. The results showed that the optimal conditions for infecting BALB/c mice with BCoV HLJ-325 strain were continuous oral gavage for 3 days with a dose of 4 × 108 TCID50. On the 7th day after infection, there was significant extensive consolidation of the lungs and thinning of the colon wall. Significant inflammation was observed in various organs, especially in the colon and alveoli, where a large number of inflammatory cells infiltrate. Both BCoV Ag and nucleic acid are positive in visceral organs. The viral load in the colon and lungs was significantly higher than that in the other organs (p < 0.001). BCoV-infected mice showed a decreasing trend in body weight starting from day 5, and there was a significant difference compared to the control group on days 6 and 7 (p < 0.001). The total number of white blood cells and lymphocytes began to decrease and was significantly lower than that in the control group 24 h after infection (p < 0.001), and gradually returned to the control level. The cytokine TNF-α, IL-1β, and IL-6 showed an increasing trend, significantly higher than the control group on day 5 and 7 (p < 0.001).These results indicate that the BCoV HLJ-325 strain can infect BALB/c mice and cause inflammatory reactions and tissue lesions. The most significant effect was observed on the seventh day after infection with a dose of 4 × 108 TCID50 and three consecutive gavages. This study established, for the first time, a BALB/c mouse model of BCoV infection, providing a technical means for evaluating the immune efficacy of BCoV vaccines and studying their pathogenic mechanisms.

Exposure to Extracellular Mitochondrial DNA During Pregnancy Induces a Pro-Inflammatory Response in Rat Placenta

Introduction: Mitochondrial DNA (mtDNA) is released in the cytosol or the extracellular space due to mitochondrial dysfunction or cell death. Extracellular mtDNA is recognized by the innate immune receptor Toll-like receptor 9 (TLR9) and induces pro-inflammatory and immunogenic responses. Circulating cell-free mtDNA (ccf-mtDNA) increases with advancing gestational age and abnormal concentrations have been reported in obstetric complications such as preeclampsia (PE). Placentas from women with PE exhibit signs of extensive inflammation; however, the contribution of ccf-mtDNA to placental inflammation during pregnancy has not been investigated. We hypothesized that in vivo exposure to extracellular mtDNA during pregnancy would induce an inflammatory response in rat placenta via activation of TLR9 signaling. Methods: We isolated mtDNA from liver of Sprague Dawley pregnant rats (gestational day: 14-15, term=22-23 days) and treated gestational age-matched dams with mtDNA (350ng/kgBW) or saline (control) via intravenous injection. Following 4 hours after treatment, maternal organs and fetoplacental units were collected and gene expression of cytokines and TLR9 were measured. Results: Plasma levels of mtDNA 4 hours after treatment were not different between saline and mtDNA-treated rats (2−ΔCT, median (IQR); saline: 2.75 (1.61) vs. mtDNA: 2.64 (1.29), p&gt;0.05). Treatment with mtDNA increased mRNA expression of pro-inflammatory tumor necrosis factor-alpha (TNF-α) (saline: 0.65 (1.1) vs. mtDNA: 2.84 (1.9), p=0.015), interleukin (IL)-6 (saline: 0.32 (0.2) vs. mtDNA: 3.37 (4.3), p=0.008), and IL-1β (saline: 0.2 (0.93) vs. mtDNA: 4.7 (6.0), p=0.01) and decreased expression of anti-inflammatory IL-10 (saline: 1.6 (0.8) vs. mtDNA: 0.6 (0.8), p=0.001) in rat placentas. Expression of macrophage marker F4/80 (saline: 0.4 (1.0) vs. mtDNA: 2.41 (4.7), p=0.04) and monocyte chemoattractant protein-1 (MCP-1) (saline: 0.68 (0.54) vs. mtDNA: 2.0(1.96), p=0.041) also increased in rat placentas in response to mtDNA treatment. To assess whether this inflammatory response was tissue-specific, we evaluated mRNA expression of inflammatory genes in maternal kidneys. Treatment with mtDNA increased the levels of IL-1β (2−ΔCT, median (IQR); saline: 1.05 (1.1) vs. mtDNA: 10.17 (8.0), p=0.008) and IL-6 (saline: 0.98 (1.76) vs. mtDNA: 6.8 (3.5), p=0.002). mtDNA treatment did not affect kidney TNF-α and IL-10 expression (p&gt;0.05). In contrast, expression of F4/80 (saline: 0.87 (2.2) vs. mtDNA: 12.5 (12.4), p=0.003) and MCP-1 (saline: 0.9 (1.7) vs. mtDNA: 7.4 (8.3), p=0.011) was greater in maternal kidneys from mtDNA-treated rats vs. controls. TLR9 expression increased in placentas (saline: 1.29 (0.5) vs. mtDNA: 4.0 (7.8), p&lt;0.0001) and maternal kidneys (saline: 1.2 (1.8) vs. mtDNA: 4.7 (4.6), p=0.045) in response to mtDNA treatment. Conclusion: Exposure to an in vivo challenge with extracellular mtDNA during pregnancy induces a pro-inflammatory response in placentas and kidneys from pregnant rats. These responses may be mediated by TLR9 signaling activation. NIH R01-HL0146562. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Electronic cigarette-induced adipose tissue inflammation is rescued by acipimox

Objective: Electronic cigarettes (e-cigarettes) are the most commonly used tobacco product in the U.S. with high frequency among youth. Our laboratory has shown that e-cigarettes induce metabolic changes and cardiac dysfunction associated with elevated serum free fatty acids (FFAs). Adipose tissue dysfunction is a proinflammatory state that mediates multiple pathogenic mechanisms in the well-known associations between cardiovascular pathology, hypertension, and metabolic syndrome. In adipose tissue, crown-like structures (CLSs) are signs of metabolic dysfunction and adipose tissue inflammation. CLSs are composed of macrophages surrounding dead or dying adipocytes. Hypothesis: We hypothesize that e-cigarettes produce inflammation in adipose tissue, which is mediated by lipolysis. Methods: C57BL/6J wild-type mice on high fat diet were treated with saline aerosol, e-cigarette with 2.4% nicotine [e-cig (2.4%)], and e-cig (2.4%) plus acipimox (an inhibitor of lipolysis) [e-cig (2.4%)+ACIP], for 12 weeks. Adipose tissue was stained with Hematoxylin and Eosin (H&amp;E). CD45 is the surface marker of immune cells. Therefore, we quantified the number of CD45+ cells in adipose tissue. Additionally, we performed a transcriptomic evaluation with Gene Set Enrichment Analysis (GSEA). Results: H&amp;E staining showed abundant CLSs in mice exposed to e-cigarettes in adipose tissue. The number of CLSs was normalized in the e-cig (2.4%)+ACIP group. E-cigarettes induced an increase of CD45+ cells in adipose tissue, which was also normalized by acipimox. GSEA of the RNA-seq data revealed upregulation of inflammatory pathways in adipose tissue from e-cigarette-treated mice, including Interferon-g and Interferon-a response, which were rescued by acipimox treatment. Summary: Inhibiting lipolysis with acipimox normalizes the inflammatory changes induced by e-cigarettes in adipose tissue. These findings suggest a functional interplay between adipose tissue and metabolic dysfunction caused by e-cigarettes. Funding: JE-D work was supported by the NIH grants: NIGMS (SC2GM135127), NIMHD (S21MD000103), the CDU Accelerating Excellence in Translational Science (AXIS) (U54MD007598-14S2), and a voucher from UCLA CTSI (UL1TR001881). TCF was supported by the California TRDRP grant (28CP-0040), DODCDMRP grant (PR190942), and NIDA (R25DA050723) grants. XMS was supported by a NIDA (R42DA044788) grant. KPR was supported DODCDMRP grant (PR190942-P1). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Metabolomic and transcriptomic alterations in the colon of mice with metabolic syndrome in the absence of inflammation

Metabolic syndrome (MetS) is characterized by a cluster of conditions including abdominal obesity, elevated blood pressure, altered lipid profiles and high blood sugar levels. These factors collectively elevate risks for cardiovascular diseases, diabetes, and metabolic dysfunction associated steatotic liver disease (MASLD). MetS impacts approximately a third of the US populace and a quarter of the global population. Despite its widespread prevalence, there are no existing medications to specifically treat MetS. With the global rise in MetS cases, understanding its underlying mechanisms is paramount. Our research emphasizes the potential physiological and metabolic disruptions within the gastrointestinal (GI) tract that might contribute to MetS manifestation. Using a mouse model of MetS (MS NASH) and healthy lean controls (C57BL/6J), we investigated the colon environment. 16S rRNA sequencing from fecal samples revealed a distinct microbiota profile in MS NASH mice, highlighted by an increase in the Lactobacillus genus. Colonic metabolome and transcriptome in MS NASH mice displayed an upregulation in anabolic pathways, like glycolysis, the pentose phosphate pathway, and the tryptophan/kynurenine pathway. Subsequent integrated analysis of these datasets unveiled potential compensatory mechanisms and pathway crosstalk, within the colonic environment. Despite these alterations, MS NASH mice showed no signs of intestinal inflammation, a finding confirmed through detailed histological and LCN-2 assessments. Additionally, there were no changes detected in genes typically associated with increased intestinal inflammation or permeability. This study provides insight in the nuanced relationship between the metabolic state, gut microbiota, and potential progression towards other metabolic disorders. Our findings highlight the significance of multi-omics data convergence in understanding the changes within the colonic environment and their implications for MetS onset and/or progression. Supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) through grant no. UL1TR001449 (E.F.C.) and in part by NIH grant P20GM121176 (E.F.C.), and the University of New Mexico Comprehensive Cancer Center with grant P30CA118100. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

A Hypovolemic Infusion of Human Methemoglobin in Golden Syrian Hamsters Provides Insight on its effect on the Microcirculation

Introduction: Hemoglobin (HbFe(II)) plays a crucial role in transporting oxygen to tissues for metabolic needs. However, this protein isn't just an oxygen carrier; it also regulates vascular tone and inflammation by its redox coupling with methemoglobin (HbFe(III)). Methemoglobin's oxidized form, Fe (III), possesses the potential to produce water from oxygen as a free energy reaction. It functions as a nitrite reductase, regulating the oxygen level in the blood and controlling vascular tone by generating nitric oxide from nitrite, thereby increasing blood flow when oxygenated hemoglobin decreases. If methemoglobin can't be reduced, it leads to the dissociation of tetrameric hemoglobin into αβ dimers, releasing heme and iron into circulation. Methods: The study involved Golden Syrian Hamsters with dorsal skin fold window chambers, observing acute methemoglobin effects via hypovolemic infusion (10% of the animal’s blood volume) compared to human hemoglobin and a lactated ringer's control. Microhemodynamics, mean arterial pressure, heart rate, blood gases, and blood properties were measured. Results: Methemoglobin did not significantly affect MAP and HR but increased arteriole diameters by 5% and venule diameter by 15% compared to baseline. However, it caused a 50% reduction in functional capillary density compared to baseline, alongside significant cardiac and kidney inflammation. Conclusion: The study concludes that a hypovolemic infusion of methemoglobin induces vasoreactivity but results in poor microcirculatory pressure and inflammation in vital organs. This demonstrates the delicate balance and potential adverse effects associated with alterations in the hemoglobin redox state and highlights the importance of maintaining its balance for vascular and organ health. Project number: R01HL159862 Project number: R01HL162120. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

ObjectiveThere is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or C-reactive...

TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice

Recent evidence of gut microbiota dysbiosis in the context of psoriasis and the increased cooccurrence of inflammatory bowel disease and psoriasis suggest a close relationship between skin and gut immune responses. Using a mouse model of psoriasis induced by the Toll-like receptor (TLR) 7 ligand imiquimod, we found that psoriatic dermatitis was accompanied by inflammatory changes in the small intestine associated with eosinophil degranulation, which impaired intestinal barrier integrity. Inflammatory responses in the skin and small intestine were increased in mice prone to eosinophil degranulation. Caco-2 human intestinal epithelial cells were treated with media containing eosinophil granule proteins and exhibited signs of inflammation and damage. Imiquimod-induced skin and intestinal changes were attenuated in eosinophil-deficient mice, and this attenuation was counteracted by the transfer of eosinophils. Imiquimod levels and the distribution of eosinophils were positively correlated in the intestine. TLR7-deficient mice did not exhibit intestinal eosinophil degranulation but did exhibit attenuated inflammation in the skin and small intestine following imiquimod administration. These results suggest that TLR7-dependent bidirectional skin-to-gut communication occurs in psoriatic inflammation and that inflammatory changes in the intestine can accelerate psoriasis.

Efficacy of lymphatic pump treatment in conjunction with methotrexate on rats with adjuvant-induced arthritis

Abstract Rheumatoid Arthritis (RA) is an autoimmune disease targeting synovial joints in which self-reactive T cells release cytokines and B cells produce self-reactive antibodies resulting in an inflammatory response. Lymphatic pump treatment (LPT) promotes lymphatic flow resulting in a flushing out of the immune-complexes and cytokines. A rat mode on RA (AIA) was used to determine whether LPT in conjunction with the anti-rheumatic drug, methotrexate (MTX), enhanced its therapeutic impact on RA. A preventative study was performed in which MTX was given along with LPT (3 times a day for 7 days) . Ankles were assessed daily for signs of inflammation. Flow cytometry was performed on spleen and popliteal lymph nodes (PLN) to determine changes in leukocyte populations. Cytokine levels were determined on ankle lysates. The study showed that MTX treatment delayed the onset of arthritis. MTX reduced the spleen weights (p&amp;lt;0.05). LPT also reduced spleen weights but did not enhance the MTX reduction. LPT reduced PLN weights compared to MTX. MTX resulted in higher numbers of CD4+ T cells and lower numbers of CD8+ T cells and B cells in spleens. PLNs treated with MTX had reduced lymphocyte numbers. MTX treatment reduced CINC-1 and TNFa levels (p&amp;lt;0.05). LPT also reduced CINC-1 levels. In conclusion, MTX treatments delayed arthritis formation in AIA rats while LPT affected both spleen and PLN weights. Thus, the addition of LPT to RA treatment showed potential benefits without negative effects.

HYPERCOAGULATION OF BLOOD AND THROMBOCYTOPENIA AFTER SARS-COV-2 – PNEUMONIA AS PREDICTORS OF AN UNFAVORABLE PROGNOSIS IN PATIENTS WITH ARTERIAL HYPERTENSION

Objective: To evaluate the dynamics of hypercoagulation parameters of blood plasma and platelets in patients with arterial hypertension (AH) in the early and late post-covid period. Design and method: The prospective study included 340 AH patients aged 41 to 89 years (mean 69; m/f 175/165) infected with SARS-CoV-2 diagnosed by PCR. Of these, 177 people (group 1) were diagnosed with acute pneumonia with the lung damage volume according to CT ranging from 15% to 85%; 163 patients (group 2) had an acute respiratory viral disease. The groups were comparable in age, gender, and concomitant comorbid pathology. Coronary heart disease (CHD) was detected in 85.6% of patients; diabetes mellitus (DM) in 31.5%. The patients were examined three times: on the 30th day from the onset of the disease, at the end of the 3rd month and after 9 months. C-reactive protein (CRP) (0-5 mg/l), ferritin (20-250 mg/l), D-dimer (0-230 ng/ml), fibrinogen (2-4 g/l), lymphocytes, and blood platelets were analyzed. Results: On day 30, group 1 patients showed signs of inflammation: ferritin 258±61.2; CRP 12.3±5.1; lymphocytes 27±8.3%; platelets 160±70.4∗10^9/l; ESR 17±13.7 mm/h. The tendency to hypercoagulation was detected by the indicators of D-dimer (715±241.3) and fibrinogen (3.7±0.9). By the end of the 3rd month, the levels of D-dimer (585±159.4; p=0.015); ferritin (177±59.1; p=0.0002) and CRP (7±5.6; p=0.001) remained elevated. Only after 9 months, D-dimer (100±9.1; p=0.0001) and CRP (2.6±0.2; p=0.0001) were normalized; lymphocyte (32±5.1%; p=0.00001) and platelets (305±69.2∗10^9/l; p=0.00001) increased with a persistent elevated ferritin level (213±124.8; p=0.047). In group 2, the indicators of hypercoagulation and inflammation were moderately elevated. Only after 9 months CRP and D-dimer levels were normalized and the number of platelets increased. Conclusions: In the early and late post-covid period, AH patients with comorbid pathology retain an inflammatory reaction and a procoagulant state, which, in combination with endothelial dysfunction, is a trigger for venous and arterial thrombosis.

Resorbable Patient-Specific Implants of Molybdenum for Pediatric Craniofacial Surgery-Proof of Concept in an In Vivo Pilot Study.

Titanium continues to be the gold standard in the field of osteosynthesis materials. This also applies to pediatric craniofacial surgery. Various resorbable materials have already been developed in order to avoid costly and risky second operations to remove metal in children. However, none of these resorbable materials have been able to completely replace the previous gold standard, titanium, in a satisfactory manner. This has led to the need for a new resorbable osteosynthesis material that fulfills the requirements for biocompatibility, stability, and uniform resorption. In our previous in vitro and in vivo work, we were able to show that molybdenum fulfills these requirements. To further confirm these results, we conducted a proof of concept in four domestic pigs, each of which was implanted with a resorbable molybdenum implant. The animals were then examined daily for local inflammatory parameters. After 54 days, the animals were euthanized with subsequent computer tomography imaging. We also removed the implants together with the surrounding tissue and parts of the spleen, liver, and kidney for histopathological evaluation. The molybdenum implants were also analyzed metallographically and using scanning electron microscopy. A blood sample was taken pre- and post-operatively. None of the animals showed clinical signs of inflammation over the entire test period. Histopathologically, good tissue compatibility was found. Early signs of degradation were observed after 54 days, which were not sufficient for major resorption. Resorption is expected with longer in situ residence times based on results of similar earlier investigations.

Choroidal manifestations of non-ocular sarcoidosis: an enhanced depth imaging OCT study

BackgroundAlthough choroidal thickening was reported as a sign of active inflammation in ocular sarcoidosis, there has been no research on the choroidal changes in non-ocular sarcoidosis (defined as systemic sarcoidosis without overt clinical signs of ocular involvement). Therefore, this study aimed to investigate choroidal structural changes in patients with non-ocular sarcoidosis.MethodsThis retrospective case–control study was conducted at Asan Medical Center, a tertiary referral center. We evaluated 30 eyes with non-ocular sarcoidosis and their age- and spherical equivalent-matched healthy control eyes. The subfoveal choroidal thickness, area ratio (Sattler layer-choriocapillaris complex [SLCC] area to Haller layer [HL] area), and choroidal vascularity index (CVI, luminal area to choroidal area) were analyzed using enhanced depth imaging in optical coherence tomography. Systemic and ocular factors associated with the choroidal thickness were investigated.ResultsCompared with the healthy control group, the non-ocular sarcoidosis group had significantly thicker subfoveal choroid (total and all sublayers [SLCC and HL]) and lower area ratio. There were no significant differences in the CVIs at all sublayers between groups. In the non-ocular sarcoidosis group, eyes under oral steroid treatment had thinner choroid than eyes under observation. In the control group, eyes with older age and more myopic spherical equivalent had thinner choroidal thickness.ConclusionTotal and all sublayers of the subfoveal choroid were significantly thicker without significant vascularity changes in non-ocular sarcoidosis eyes than in healthy control eyes. The degree of choroidal thickening was disproportionally greater at HL than at SLCC. These characteristic choroidal changes may be the subclinical manifestations in non-ocular sarcoidosis.

Antibiotic resistance of microorganisms isolated from the urine of patients before surgical treatment for benign prostatic hyperplasia: results from a 7-year single-center study

Introduction. The tendency of microorganisms to develop resistance mechanisms is a widely discussed and significant problem worldwide. Studying regional differences in the qualitative characteristics of microorganisms provides valuable information for empirically preventing and treating infectious complications, as well as providing an enhanced understanding of the variability in microbial community properties within the clinical context of diseases and patients' comorbidity status.Objective. To assess the antibiotic resistance of microorganisms isolated in high titers from the urine samples of patients with benign prostate hyperplasia (BPH) prior to surgery.Materials &amp; Methods. This single-center, retrospective study conducted from March 2016 to February 2023 included 59 suprapubic-draining BPH-patients (Group I), 46 drainage-free BPH-patients with leukocyturia (Group II), and 44 drainage-free BPH-patients and no leukocyturia (Group III). Inclusion criteria: indications for BPH surgery, no history of sexually transmitted diseases, no symptoms of urinary tract infection, and no prostate cancer. The patient's voluntary informed consents to participate were also obtained.Results. The rates of resistance to ciprofloxacin in patients of Group I were statistically significantly higher compared to Group II (85.7% vs 55.6%, p = 0.002). Resistance of gram-negative microorganisms to meropenem and imipenem was higher in Group III compared to Group I (31.1% vs 13.7%, p = 0.006 for meropenem and 44.5% vs 9.8%, p = 0.001 for imipenem, respectively). Resistance of Gram-positive microorganisms to ampicillin in Groups I to III was 13.6%,6.3% and 20.0%, respectively with no significant difference between groups (p &gt; 0.05). However, there was extremely high resistance among verified Gram-positive organisms to all the drugs in the fluoroquinolone class (ciprofloxacin, norfloxacin, levofloxacin) ranged from 63.6% to 80.0%.Conclusion. The present study demonstrates that the isolation frequency of antibiotic-resistant microorganisms from the urine sample of drainage-free BPH-patients or no clinical and laboratory signs of inflammation in the urinary tract is high. The presence of antibiotic resistance provides risks for developing difficult-to-control infectious complications. Currently, assessment of urine-derived microbial antibiotic resistance should be considered in every BPH-patient with indications for surgical management of bladder outlet obstruction, regardless of the presence of risk factors.

P111 Reliability of quantitative sensory testing, disease activity score 28, ultrasound and central aspects of pain questionnaire in individuals with rheumatoid arthritis

Abstract Background/Aims Disease Activity Score 28 (DAS28), ultrasound, quantitative sensory testing (QST) and central aspect of pain (CAP) questionnaire measure disease activity and pain hypersensitivity. We investigated their inter-rater and test-retest reliability in Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA) participants. Methods Participants who attended the CAP-RA study visit and agreed to one or more reliability assessments were included. The same two raters completed all assessments, including clinical examination for DAS28, using a single blood sample per participant. QST modalities in the sequence: Pressure Pain detection Threshold (PPT) at the medial joint line of the most painful knee, tibialis anterior and contralateral brachioradialis, Temporal Summation (TS) at rectus femoris of the most painful knee and Conditioned Pain Modulation (CPM), with ischaemic arm pain conditioning and PPT at tibialis anterior. Ultrasound followed the Backhaus 7 protocol, plus the knee. Two trained sonographers scored each joint scan for grey scale (GS), power Doppler and a combined score (PDUS) using EULAR-OMERACT methodology. Joint scores were summated to give an overall score for GS, Doppler and PDUS. Participants could complete questionnaires at invitation, prior to and at baseline, 1-week post-baseline, prior to and at follow-up visit. Any combination of questionnaires completed within 7 days of each other assessed repeatability. Data were assessed for normality, interclass correlation coefficients, and Bland and Altman plots in R studio. Results 196 people were recruited into CAP-RA (median (IQR)) age 66 (58-75) y, 139 (75%) female, 190 (98%) white. 97 (49%) undertook study visits. Characteristics of the 66 people undertaking reliability did not significantly differ from the total population. Measurements are shown in Table 1. Moderate to excellent reliability was found across all measures except CPM (Table 1). The swollen joint count was the least reliable of the DAS28 components. Conclusion Measures of inflammatory disease activity and pain sensitivity are at least moderately reliable within a research context. Only low reliability for CPM might indicate imprecision, or reflect fluctuations in symptoms or pain sensitivity. High reliability of DAS28 and US might reflect relative stability of clinical signs of inflammation. Suppressing day-to-day fluctuations could reduce the unpredictability of rheumatoid arthritis. Disclosure S.L. Smith: None. V. Georgopoulos: None. O. Ifesemen: None. E. Ferguson: None. R.J. Wakefield: None. D. Wilson: None. P. Buckley: None. D. Platts: None. S. Ledbury: None. D.F. McWilliams: Grants/research support; Eli Lilly, Pfizer, GSK, Orion, UCB. D.A. Walsh: Grants/research support; Eli Lilly, Pfizer, GSK, Orion, UCB.

Healing effect of the polysaccharide extract from Cissus sicyoides leaves in a rat model of excisional cutaneous wounds

The healing process is a physiological event involving cellular and molecular mechanisms to remove and replace damaged tissues, allowing new extracellular matrix synthesis. Based on previous studies showing antinociceptive, anti-inflammatory and antioxidative effects of the polysaccharide-rich extract of Cissus sicyoides leaves (PE-Cs) in classical inflammation models, this study evaluated the PE-Cs effect in the rat model of excisional cutaneous wound. The topical treatment with PE-Cs (0.01–1%) for 14 days reduced (43–50%, 5 – 7th day) the wound area and increased the nociceptive threshold (38.85–47.65%, 6th hour - 7th day). PE-Cs reduced leukocyte infiltration (42% - 2nd day and 84% - 5th day) and increased fibroblasts/myofibroblasts (59% - 5th day and 24% - 7th day), collagen deposition (30% - 5th day and 23% - 7th day) and blood vessels (60% - 5th day and 50% - 7th day). PE-Cs reduced the oxidative stress marker MDA (33% - 2nd day), and increased GSH levels (35–27%, 2 – 7th day). In conclusion, PE-Cs acts in the inflammatory and proliferative phases of the rat healing process via acceleration of wound closure, reduction of inflammatory signs, oxidative stress markers and stimulation of fibroplasia, collagenesis and increased blood vessel count.

Evaluation of anti-inflammatory properties on the surface of dental implants depending on the type of processing (Part 1)

The aim. To study of the anti-inflammatory properties of the surface of commercial dental implants with different processing methods using the example of the course of the first stage of implantation. Materials and methods. Dental implants made of titanium with 3D Active and Xpeed surface treatment were used. The surface microstructure and biocompatibility of the samples, surface corrosion, elemental analysis of the surface was studied. The assessment of the severity of peri-implantitis and mucositis based on the depth of the peri-implant pocket and bleeding during probing, determination of the coefficient of stability of implants (KSI) is given. Median test (χ2), Kruskel–Wallis test (H), univariate variance analysis (F) were used for multiple comparison of samples. The difference in parameters was considered statistically significant at the p ≤ 0.05 level. Results. The surfaces of 3D Active implants are monolithic with rounded pores in the form of wells of different diameters and depths; the upper layer of the Xpeed sample consists of closely adjacent to each other fragments of a rectangular or polygonal shape, in the form of tiles, leaving rectangular faces on the outside. On the surface of the 3D Active samples, in addition to oxygen and carbon, there was phosphorus – 5.04 wt%, as well as S, Ca, Na, Zr, Zn which weight percentage did not exceed 1 wt%. A significant difference in the elemental composition of Xpeed implants was the presence of chlorine 0.07 wt% and 0.93 wt%, silicon – 0.10 wt% and 0.14 wt%, aluminum 0.06 wt% and 0.23 wt%, respectively, with the latter has a significant advantage in these elements. Xpeed had an insignificant weight percentage of iron in its composition – 0.12 wt%. The assessment of cell adhesion to the surface of the samples on the first day of incubation demonstrated that the samples with the Xpeed and 3D Active surfaces did not have a statistically significant difference between them. Also, on the 7th day of incubation, the level of reduction of resazurin in Xpeed was lower, no significant difference was observed (p &gt; 0.05). The clinical signs of bone tissue resorption were identified in 36.4 % of 3D Active implants and 60.0 % of Xpeed implants (p = 0.3); inflammation of the mucous membrane – in the areas of installation of 54.5 % of 3D Active implants. No signs of mucositis were detected around the Xpeed implants (p = 0.23). 9.1 % of 3D Active implants were “lost”; no cases of loss of Xpeed implants have been identified. The KSI of 3D Active – 64.0 ± 5.9 units, Xpeed – 65.1 ± 3.7 units. Conclusions. According to KSI indicators, titanium implants with Xpeed coating (65.1 ± 3.7 units) and 3D Active (64.0 ± 5.9 units) showed the same capabilities. Bone tissue resorption without signs of inflammation is more common around Xpeed-coated implants than 3D Active-coated implants. Clinical signs of inflammation are more frequent and more severe around implants with a 3D Active coating, which affected both the severity of the course of the first stage of implantation and its results. Xpeed-coated implants are more reliable than 3D Active: loss among 3D Active implants was 9.1 %, Xpeed – 0.0 %.

HBeAg-positive patients hepatic tissue inflammatory activity and influencing factors during normal ALT and indeterminate phases

Objective: To analyze the hepatic tissue inflammatory activity and influencing factors in HBeAg-positive patients during normal alanine aminotransferase (ALT) and indeterminate phases so as to provide a basis for evaluating the disease condition. Methods: Patients with HBeAg-positive with normal ALT and HBV DNA levels below 2 × 10(7) IU/ml from January 2017 to December 2021 were selected as the study subjects. A histopathologic liver test was performed on these patients. Age, gender, time of HBV infection, liver function, HBsAg level, HBV DNA load, genotype, portal vein inner diameter, splenic vein inner diameter, splenic thickness, and others of the patients were collected. Significant influencing factors of inflammation were analyzed in patients using logistic regression analysis, and its effectiveness was evaluated using receiver operating characteristic (ROC) curves. Results: Of the 178 cases, there were 0 cases of inflammation in G0, 52 cases in G1, 101 cases in G2, 24 cases in G3, and one case in G4. 126 cases (70.8%) had inflammatory activity ≥ G2. Infection time (Z=-7.138, P<0.001), γ-glutamyltransferase (t =-2.940, P=0.004), aspartate aminotransferase (t =-2.749, P=0.007), ALT (t =-2.153, P=0.033), HBV DNA level (t =-4.771, P=0.010) and portal vein inner diameter (t =-4.771, P<0.001) between the ≥G2 group and < G2 group were statistically significantly different. A logistic regression analysis showed that significant inflammation in liver tissue was independently correlated with infection time [odds ratio (OR)=1.437, 95% confidence interval (CI): 1.267-1.630; P<0.001)] and portal vein inner diameter (OR=2.738, 95% CI: 1.641, 4.570; P<0.001). The area under the curve (AUROC), specificity, and sensitivity for infection time and portal vein inner diameter were 0.84, 0.71, 0.87, 0.72, 0.40, and 0.95, respectively. Conclusion: A considerable proportion of HBeAg-positive patients have inflammation grade ≥G2 during normal ALT and indeterminate phases, pointing to the need for antiviral therapy. Additionally, inflammatory activity has a close association with the time of infection and portal vein inner diameter.